Price Action to Note: What Will Happen to LeMaitre Vascular Inc Next? The Stock Just Reaches 52-Week High

Price Action to Note: What Will Happen to LeMaitre Vascular Inc Next? The Stock Just Reaches 52 Week High

The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) hit a new 52-week high and has $40.48 target or 70.00% above today’s $23.81 share price. The 5 months bullish chart indicates low risk for the $440.02 million company. The 1-year high was reported on Nov, 11 by If the $40.48 price target is reached, the company will be worth $308.01M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 2.19% or $0.51 during the last trading session, hitting $23.81. About 188,292 shares traded hands or 26.12% up from the average. LeMaitre Vascular Inc (NASDAQ:LMAT) has risen 51.69% since April 11, 2016 and is uptrending. It has outperformed by 45.55% the S&P500.

LeMaitre Vascular Inc (NASDAQ:LMAT) Ratings Coverage

Out of 9 analysts covering LeMaitre Vascular (NASDAQ:LMAT), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. LeMaitre Vascular has been the topic of 22 analyst reports since July 29, 2015 according to StockzIntelligence Inc. On Monday, December 7 the stock rating was maintained by TH Capital with “Buy”. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) has “Outperform” rating given on Thursday, April 21 by Cowen & Co. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) earned “Buy” rating by Canaccord Genuity on Tuesday, May 3. Benchmark maintained the shares of LMAT in a report on Wednesday, July 29 with “Buy” rating. Sidoti downgraded LeMaitre Vascular Inc (NASDAQ:LMAT) on Thursday, September 22 to “Neutral” rating. As per Wednesday, July 29, the company rating was maintained by TH Capital. The rating was maintained by Dougherty & Company on Monday, December 7 with “Buy”. The rating was upgraded by Barrington Research to “Outperform” on Wednesday, October 28. The company was maintained on Tuesday, May 3 by Roth Capital. Barrington Research maintained LeMaitre Vascular Inc (NASDAQ:LMAT) on Thursday, February 25 with “Outperform” rating.

According to Zacks Investment Research, “LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time.”

Insitutional Activity: The institutional sentiment decreased to 1.24 in 2016 Q2. Its down 0.79, from 2.03 in 2016Q1. The ratio fall, as 6 funds sold all LeMaitre Vascular Inc shares owned while 31 reduced positions. 12 funds bought stakes while 34 increased positions. They now own 10.35 million shares or 1.88% more from 10.16 million shares in 2016Q1.
Analytic Ltd Liability Corp last reported 92,495 shares in the company. First Light Asset Lc holds 385,562 shares or 2.55% of its portfolio. Perkins Capital Mgmt Inc holds 2.26% of its portfolio in LeMaitre Vascular Inc (NASDAQ:LMAT) for 138,358 shares. Wells Fargo And Mn holds 0% or 22,810 shares in its portfolio. Globeflex Cap Limited Partnership accumulated 76,202 shares or 0.3% of the stock. Allianz Asset Management Ag reported 336,656 shares or 0% of all its holdings. Deutsche Financial Bank Ag accumulated 8,449 shares or 0% of the stock. Goldman Sachs Gru, a New York-based fund reported 35,872 shares. Invesco Limited has 69,324 shares for 0% of their US portfolio. Manufacturers Life Insurance Communication The last reported 0% of its portfolio in the stock. Rhumbline Advisers, a Massachusetts-based fund reported 11,252 shares. California Pub Employees Retirement Sys reported 91,747 shares or 0% of all its holdings. Northern Tru holds 187,973 shares or 0% of its portfolio. Nationwide Fund Advsrs holds 9,293 shares or 0% of its portfolio. Continental Lc last reported 0.37% of its portfolio in the stock.

Insider Transactions: Since May 16, 2016, the stock had 0 insider buys, and 27 insider sales for $7.62 million net activity. LeMaitre George W also sold $1.10M worth of LeMaitre Vascular Inc (NASDAQ:LMAT) shares. On Tuesday, September 6 the insider Roberts David B sold $401,302. Another trade for 11,905 shares valued at $182,373 was sold by Gebauer Peter R. The insider Kamke Trent G sold 2,510 shares worth $37,650. Shares for $390,560 were sold by LeMaitre Cornelia W. $132,001 worth of shares were sold by Jasinski Lawrence J on Tuesday, August 9.

More news for LeMaitre Vascular Inc (NASDAQ:LMAT) were recently published by:, which released: “LeMaitre Vascular Acquires Restore Flow Allografts” on November 10, 2016.‘s article titled: “LeMaitre Vascular Buys Restore Flow Allografts for $14M” and published on November 11, 2016 is yet another important article.

LMAT Company Profile

LeMaitre Vascular, Inc., incorporated on June 15, 1998, is a well-known provider of medical devices for the treatment of peripheral vascular disease. The Firm and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. The Company’s portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch. The Company’s principal product offerings are sold across the world, primarily in the United States, Europe, Asia and the Pacific Rim. The Company’s subsidiaries include LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, LeMaitre Vascular Pty Ltd, and Xenotis Pty Ltd.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment